Home | EndoTODAY | EndoATLAS

Beginner | ESA | Schedule | OPD

Seminars | Atlas | Recent | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[È­»ý¼º À§¿°. Àå»óÇÇÈ­»ý. Metaplastic gastritis] - ðû

1. È­»ý¼º À§¿° °­ÀÇ·Ï (ÀÌÁØÇà, 2016)

2. ³»½Ã°æ ¼Ò°ß Endoscopic findings

3. ȯÀÚ ¼³¸í¼­

4. 2025³â ¹Ì±¹ÀÇ ¾ûÅ͸® °¡À̵å¶óÀÎ - ¿ì¸®³ª¶ó Çö½Ç°ú ³Ê¹« µ¿¶³¾îÁø À̾߱âÀÎÁö¶ó ÇÒ ¸»ÀÌ ¾ø½À´Ï´Ù

5. FAQ (ÀÌÁØÇà, 2016)

6. References

Complete metaplasiaIncomplete metaplasia
Small intestinal phenotype
Brush border
Eosinophilic enterocytes
Well formed goblet cells
Colonic phenotype
No brush border
Irregular mucin droplets


1. È­»ý¼º À§¿° °­ÀÇ·Ï (ÀÌÁØÇà, 2016)

2016³â ÇÑ Çмú´ëȸ °­ÀÇ·ÏÀÔ´Ï´Ù. Âü°íÇϽñ⠹ٶø´Ï´Ù.

PDF 0.4 M


2. ³»½Ã°æ ¼Ò°ß

À§ °ÅÀÇ Àüü°¡ À§Ã༺ È­»ý¼º º¯È­°¡ ÇöÀúÇÏ¿´´ø 70´ë ³²¼º

À§ÀüÁ¤ºÎ´Â ºñ±³Àû ±ú²ýÇѵ¥ À§Ã¼ºÎ È­»ý¼º º¯È­°¡ ÇöÀúÇÑ °æ¿ì

È­»ý¼º º¯È­°¡ ½ÉÇÏ¿© ±ô¦ ³î¶ó´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

È­»ý¼º º¯È­°¡ ÀüÁ¤ºÎ¿¡¼­´Â ´ë´ÜÇÏÁö ¾ÊÀºµ¥ fundus¿¡¼­ ½ÉÇÏ¿© ±ô¦ ³î¶ó´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

À§Ã༺ º¯È­¿Í È­»ý¼º º¯È­´Â ÇÔ²² °üÂûµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀüÁ¤ºÎ´Â È­»ý¼º º¯È­°¡ ½ÉÇß°í, üºÎ´Â À§Ã༺ º¯È­°¡ ½ÉÇß´ø ȯÀÚÀÔ´Ï´Ù. Chronic atrophic and metaplastic gastritis·Î Áø´ÜÇÏ¿´½À´Ï´Ù.

½ÉÇÑ À§Ã༺ È­»ý¼º À§¿°À¸·Î ù ÁÙ Áß°£»çÁø Áß¾Ó ¾à°£ ¾Æ·¡¿¡ ÀÛÀº noduleÀÌ ÀÖ°í Á¶Á÷°Ë»ç¿¡¼­ ¼±Á¾À¸·Î ³ª¿È

10³â Àü À§±Ë¾çÀ¸·Î Á¦±ÕÄ¡·á¸¦ ¹ÞÀ¸¼Ì´ø ȯÀÚ¿¡¼­ ¹ß°ßµÈ ±ÙÀ§ºÎ À§Á¡¸·ÀÇ ÇöÀúÇÑ È­»ý¼º º¯È­

À§Ã¼»óºÎ ¼Ò¸¸ À§¾Ï ȯÀÚÀÇ À§ÀüÁ¤ºÎÀÇ ÇöÀúÇÑ À§Ã༺ º¯È­

À§ ȯÀÚÀÇ ÀüÁ¤ºÎ Á¶Á÷°Ë»ç¿¡¼­ proper gland°¡ ¼Ò½ÇµÇ¾ú´Ù.

È­»ý¼º À§¿°ÀÇ metaplatic nodule

À§ ȯÀÚÀÇ Á¶Á÷°Ë»ç

Pyloric ring ´ë¸¸ÂÊ ÀÛÀº metaplastic nodule

À§ ȯÀÚÀÇ Á¶Á÷°Ë»ç

À§ ȯÀÚÀÇ Á¶Á÷°Ë»ç


3. È­»ý¼º À§¿° ȯÀÚ¼³¸í¼­

È­»ý¼º À§¿° (Àå»óÇÇÈ­»ý)Àº ¸Å¿ì ÈçÇÕ´Ï´Ù. À§¾ÏÀÇ À§ÇèÀÎÀÚ·Î ¾Ë·ÁÁ® Àִµ¥, À§¾Ï ¹ß»ý·ü ¼¼°è 3À§ÀÎ ¿ì¸®³ª¶ó¿¡¼­´Â ±× Àǹ̰¡ ºÒ¸íÈ®ÇÕ´Ï´Ù. (1) È­»ý¼º À§¿°ÀÌ ¾ø´õ¶óµµ À§¾ÏÀº ¾ó¸¶µçÁö ¹ß»ýÇϰí ÀÖÀ¸¸ç, (2) ÀÌ¹Ì Àü±¹¹Î À§¾Ï °ËÁø »ç¾÷ÀÌ ÁøÇàµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÅëÀÏµÈ °¡À̵å¶óÀÎÀº ¾øÁö¸¸, ÀÇ»çµéÀÇ º¸ÆíÀûÀÎ ÀÔÀåÀº º°´Ù¸¥ Àǹ̸¦ ºÎ¿©ÇÏÁö ¸»ÀÚ´Â °ÍÀÔ´Ï´Ù.

³»½Ã°æ °Ë»ç¿¡¼­ °ü½ÉÀÖ°Ô º¸´Â °ÍÀº À§¿°ÀÌ ¾Æ´Ï°í ±Ë¾ç, ¾Ï, ¼±Á¾ µî º¸´Ù Àǹ̰¡ ¸íÈ®ÇÑ ÁúȯÀÔ´Ï´Ù. À§¿°¿¡ ´ëÇÑ ³»½Ã°æÀû Æò°¡´Â Àϰü¼ºÀÌ ³·¾Æ¼­ Ä¡·á ¹æÄ§ °áÁ¤ÀÇ ±Ù°Å·Î »ï±â´Â ¾î·Æ½À´Ï´Ù.

¾àÀº ÇÊ¿ä¾ø°í »ó½Ä¿¡ ÁØÇÑ °Ç°­ÇÑ ½Ä»ýȰ°ú 1³â ÈÄ ³»½Ã°æ °Ë»ç¸¦ ±ÇÇÕ´Ï´Ù. (¿¬°íÁö)

°£È¤ Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÚ°¡ ÀÖ½À´Ï´Ù. ¿øÇϽøé È£±â°Ë»ç(ºñ±Þ¿©ÀÔ´Ï´Ù. 4-5¸¸¿ø Á¤µµ °Ë»ç·á º»ÀÎ ºÎ´ã)¸¦ ÇØ º¼ ¼ö ÀÖ½À´Ï´Ù. (2023-1-16. ÀÌÁØÇà)


°Ë»ç °£°ÝÀ» ´ÜÃàÇÏ·Á´Â ȯÀںеéÀÌ °è½Ê´Ï´Ù. ±×·¯Áö ¸¶½Ã¶ó°í ¼³¸íµå¸³´Ï´Ù.


4. 2025³â ¹Ì±¹ÀÇ ¾ûÅ͸® °¡À̵å¶óÀÎ - ¿ì¸®³ª¶ó Çö½Ç°ú ³Ê¹« µ¿¶³¾îÁø À̾߱âÀÎÁö¶ó ÇÒ ¸»ÀÌ ¾ø½À´Ï´Ù. (Morgan. ACG 2025)

2025³â ¹Ì±¹¿¡¼­ ³ª¿Â °¡À̵å¶óÀÎ ÀÔ´Ï´Ù (Morgan. ACG 2025). ¿ì¸®³ª¶ó Çö½Ç°ú ³Ê¹« µ¿¶³¾îÁø À̾߱âÀÎÁö¶ó ÇÒ ¸»ÀÌ ¾ø½À´Ï´Ù. ÇѽÉÇÑ °¡À̵å¶óÀÎÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.

Gastric premalignant conditions (GPMC) are common and include atrophic gastritis, gastric intestinal metaplasia, dysplasia, and certain gastric epithelial polyps. GPMC have an increased risk of progression to gastric adenocarcinoma. Gastric cancer (GC) in the United States represents an important cancer disparity because incidence rates are 2- to 13-fold greater in non-White individuals, particularly early-generation immigrants from regions of high GC incidence. The US 5-year survival rate for GC is 36%, which falls short of global standards and is driven by the fact that only a small percentage of GC in the US is diagnosed in the early, curable stage. This document represents the first iteration of American College of Gastroenterology guidelines on this topic and encompasses endoscopic surveillance for high-risk patients with GPMC, the performance of high-quality endoscopy and image-enhanced endoscopy for diagnosis and surveillance, GPMC histology criteria and reporting, endoscopic treatment of dysplasia, the role of Helicobacter pylori eradication, general risk reduction measures, and the management of autoimmune gastritis and gastric epithelial polyps. There is insufficient evidence to make a recommendation on upper endoscopic screening for GC/GPMC detection in US populations deemed high-risk for GC. Surveillance endoscopy is recommended for individuals at high risk for GPMC progression, as defined by endoscopic, histologic, and demographic factors, typically every 3 years, but an individualized interval may be warranted. H. pylori testing, treatment, and eradication confirmation are recommended in all individuals with GPMC. Extensive high-quality data from US populations regarding GPMC management are lacking, but continue to accrue, and the quality of evidence for the recommendations presented herein should be interpreted with this dynamic context in mind. The GPMC research and education agendas are broad and include high-quality prospective studies evaluating opportunistic endoscopic screening for GC/GPMC, refined delineation of what constitutes "high-risk" populations, development of novel biomarkers, alignment of best practices, implementation of training programs for improved GPMC/GC detection, and evaluation of the impact of these interventions on GC incidence and mortality in the US.

¸î °¡Áö ÀǰßÀÔ´Ï´Ù. À§¾Ï ÈÄÁø±¹ ¹Ì±¹¿¡¼­ ½ÃÇàÇÏ´Â ¾ûÅ͸® °Ë»ç¿Í ¾ûÅ͸® °¡À̵å¶óÀÎÀ¸·Î ÀÌÇØÇÏ¸é µÇ°Ú½À´Ï´Ù.

Syndney protocol biopsy¸¦ 5°÷¿¡¼­ ÇÏ¿© ÀüÁ¤ºÎ ¼Ò¸¸°ú ÀüÁ¤ºÎ ´ë¸¸ Á¶Á÷°Ë»ç¸¦ ÇÑ Åë¿¡, À§°¢°ú À§Ã¼ºÎ ¼Ò¸¸°ú À§Ã¼ºÎ ´ë¸¸ÀÇ Á¶Á÷°Ë»ç¸¦ ¶Ç ´Ù¸¥ ÇÑ Åë¿¡ ´ãµµ·Ï ±ÇÇϰí ÀÖ½À´Ï´Ù. ¸¸¾à ¾ÏÀ̳ª dysplasia°¡ ³ª¿À¸é ¾îµð Á¶Á÷°Ë»ç¿¡¼­ ¾ÏÀ̳ª dysplasia°¡ ³ª¿Ô´ÂÁö ¾Ë ¼ö ¾ø½À´Ï´Ù. ÇÑ °÷ÀÇ Á¶Á÷Àº ÇÑ °÷¿¡ ´ã´Â´Ù´Â °ÍÀº ¸Å¿ì Áß¿äÇÑ ¿øÄ¢À¸·Î ²À ÁöÄÑÁ®¾ß ÇÒ °Í °°½À´Ï´Ù.

Åë»ó °Ë»ç¿¡¼­ intestinal metaplasia¸¦ complete¿Í incomplete·Î ³ª´©¶ó´Â °ÍÀÔ´Ï´Ù. Special stainingÀÌ ¾øÀ¸¸é ÇÒ ¼ö ¾ø´Â ÀÏÀÌÁö¿ä. ¹Ì±¹ Á¶Á÷°Ë»ç°¡ ¾öû ºñ½Ñ ÀÌÀ¯¸¦ ¾Ë ¼ö ÀÖ½À´Ï´Ù. ¿ì¸®³ª¶ó³ª ÀϺ» ¾îµð¿¡¼­µµ ±×·¸°Ô ÇÏ´Â °÷ÀÌ ¾ø½À´Ï´Ù. À§¾Ï ÈÄÁø±¹ ¹Ì±¹¿¡¼­³ª ÀÖÀ» ¼ö ÀÖ´Â ÀÏÀÔ´Ï´Ù.

Dysplasia¿¡¼­ Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á°¡ ¾Ï¹ß»ýÀ» ÁÙÀδٴ ±Ù°Å¾ø´Â À̾߱Ⱑ ¹öÁ£ÀÌ ¾²¿© ÀÖ½À´Ï´Ù.

Intestinal metaplasia³ª atrophic gastritis°¡ À־ high risk°¡ ¾Æ´Ï¸é ¾Æ¿¹ ÃßÀû³»½Ã°æÀ» ±ÇÇÏÁö ¾Êµµ·Ï µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ¶ÇÇÑ ¾à°£ ¿ô±ä À̾߱âÀε¥, east asianÀº ¸ðµÎ °íÀ§Ç豺À̹ǷΠ3³â ÈÄ Àç°ËÀ» ÇØ¾ß ÇÕ´Ï´Ù. ÇϾá ÄÚÄ«½Ã¾È »©°í ¸ðµÎ °íÀ§Ç豺À̶ó°í ÇÕ´Ï´Ù. ÀÎÁ¾ Â÷º° ¾Æ´Ñ°¡¿ä?

DysplasiaÀε¥ ³»½Ã°æ¿¡¼­ º´¼Ò°¡ º¸ÀÌÁö ¾ÊÀ¸¸é ¾î¶»°Ô Ç϶ó°í µÇ¾î ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç¸¦ blindÇÏ°Ô ÇÏ°í ¶Ç ¸¶±¸ ¼¯±â ¶§¹®¿¡ dysplasia°¡ ³ª¿Ô´Âµ¥ ¾îµðÀÎÁö ¸ð¸£´Â ¿¹°¡ »ý±â´Â °ÍÀÔ´Ï´Ù. Target biopsy ±Ù°£ÀÇ °Ë»çÇϰí Ä¡·áÇÏ´Â ¿ì¸®³ª¶ó³ª ÀϺ»°ú´Â ÀüÇô ´Ù¸¥ À̾߱⸦ Çϰí ÀÖ½À´Ï´Ù.


[FAQ]

[2017-6-15. ¾Öµ¶ÀÚ Áú¹®]

¾ó¸¶ Àü Á¾ÆíÀÇ °Ç°­ÇÁ·Î±×·¥¿¡¼­ À§³»½Ã°æ°ú °ü·ÃµÈ ÁÖÁ¦¸¦ ´Ù·ç´Âµ¥, ÇÔ±â¹é ±³¼ö´Ô²²¼­ Ã⿬Áøµé ³»½Ã°æÀ» ¼³¸íÇϽø鼭 À§Ã༺ À§¿°°ú Àå»óÇÇÈ­»ý¿¡ ´ëÇØ¼­ Á¦±ÕÄ¡·á¸¦ ÇØ¾ßÇÑ´Ù°í ÇÏ¿© Á¦ ȯÀÚµéÀÌ Á¦±ÕÄ¡·á¸¦ ÇÏ°í ½Í´Ù°í ³»¿øÇÑ È¯ÀÚµéÀÌ ÀÖ¾ú½À´Ï´Ù. ¹æ¼Û¿¡ ±×·± ³»¿ëÀÌ ³ª¿Ã Á¤µµ¸é ÀÌÁ¦ °ø½ÄÈ­ ÇØ¼­ Á¦±ÕÄ¡·á ¹üÀ§¸¦ ³ÐÇô´Þ¶ó°í °ø·ÐÈ­ÇÏ¸é ¾ÈµÇ´Â °ÍÀÎÁö ´ä´äÇÏ¿© ¸ÞÀÏ º¸³»º¾´Ï´Ù. Ȥ½Ã ¹æ¼Û¿¡¼­ ±×·± ³»¿ëÀÌ ³ª¿ÔÀ»¶§´Â ¾î¶»°Ô ´ëÃ³ÇØ¾ß ÇÏ´ÂÁö ¾Ë°í ½Í½À´Ï´Ù.

[2017-6-15. ÀÌÁØÇà ´äº¯]

Ç︮ÄÚ¹ÚÅÍÇÐȸ¿¡¼­ Á¦±ÕÄ¡·áÀÇ ÀûÀÀÁõ È®´ë¿¡ ´ëÇÑ ÀǰßÀ» ¿©·¯¹ø ³½ ÀûÀÌ ÀÖ½À´Ï´Ù. ´ç¿¬È÷ ÀûÀÀÁõ È®´ëÀÔ´Ï´Ù. ¸¶Áö¸· °¡À̵å¶óÀÎÀº 2013³â¿¡ ¹ßÇ¥µÇ¾ú´Âµ¥ ¸·¹«°¡³»ÀÔ´Ï´Ù. ±Ç°í¼öÁذú ±Ù°Å ¼öÁØÀÌ ITP´Â 1A, functional dyspepsia´Â 2AÀε¥ À̰ÍÁ¶Â÷ ¹Þ¾ÆµéÀÌÁö ¾Ê°í ÀÖ´Â »óȲÀÔ´Ï´Ù. Atrophic and metaplastic gastritis´Â 2CÀÔ´Ï´Ù.

PDF 0.8M

Á¤ºÎ(½ÉÆò¿ø)¿¡¼­ ÀûÀÀÁõÀ» ³ÐÇôÁÖ±â Àü±îÁö´Â atrophic/metaplastic gastritis¿¡ ´ëÇÑ Á¦±ÕÄ¡·á´Â ¾ÆÁ÷ ºÒ¹ýÀÔ´Ï´Ù. ¿©·¯ ±³¼ö´ÔµéÀÌ ÀÚ½ÅÀÇ ÀǰßÀ» ¾ð·Ð¿¡¼­ ¹àÈ÷´Â °ÍÀº ³ª»Û ÀÏÀº ¾Æ´Õ´Ï´Ù. ÀûÀÀÁõ¿¡ ´ëÇÑ ±âÁØÀ» ³Ê¹« tightÇÏ°Ô ¿î¿µÇϸ鼭 off label ó¹æÀ» Çã¿ëÇÏÁö ¾Ê´Â ³ª»Û Á¦µµ°¡ ¹®Á¦ÀÔ´Ï´Ù.

Àú´Â °ú°Å¿¡´Â atrophic/metaplastic gastritis¿¡¼­ Àý´ë·Î ó¹æÇÏÁö ¾Ê¾Ò½À´Ï´Ù. ȯÀÚ°¡ °­·ÂÈ÷ ¿ä±¸Çϸé "Àú¿¡°Ô ºÒ¹ýÁø·á¸¦ °­¿äÇÏÁö ¸»¾ÆÁÖ¼¼¿ä. Ȥ½Ã ¿øÇÏ½Ã¸é ¾Æ´Â ÀÇ»ç ã¾Æ°¡¼­ ¸ô·¡ ºÒ¹ý ó¹æ ¹ÞÀ¸¼¼¿ä. ¿µ ¿øÇÏ½Ã¸é ±¹°¡±â°ü¿¡ ¹Î¿øÀ» ³»¼¼¿ä."¶ó°í ´äÇß½À´Ï´Ù. ´ëÇѹα¹ ±¹¹ÎÀº ¾Æ¹«¸® ¸¶À½¿¡ µéÁö ¾Ê´õ¶óµµ ´ëÇѹα¹ÀÇ ¹ýÀ» ÁöÄÑ¾ß ÇÑ´Ù´Â ÀÔÀåÀ̾ú´ø °ÍÀÌÁö¿ä.

¼ö ³â ÀüºÎÅÍ´Â flexibleÇÏ°Ô ¿î¿µÇϰí ÀÖ½À´Ï´Ù. Àúµµ ³ªÀ̸¦ ¸ÔÀº ¸ð¾çÀÔ´Ï´Ù. ±¹°¡ Áöħµµ Áß¿äÇÏÁö¸¸ ȯÀÚ¸¦ ºÒ½ÖÈ÷ ¿©°Ü¾ß ÇÑ´Ù´Â »ý°¢À» ÇÏ°Ô µÇ¾ú½À´Ï´Ù. À߸øµÈ Á¤Ã¥À» °¡Áø ±¹°¡ÀÇ ±¹¹ÎÀ̶ó°í ¹«Á¶°Ç À߸øµÈ Ä¡·á¸¦ ¹Þ°Ô ¹æÄ¡Çؼ­´Â ¾ÈµÇ´Ï±î¿ä. ±×·¸´Ù°í Á¦°¡ °è¼Ó ºÒ¹ý Áø·á¸¦ ÇÒ ¼ö´Â ¾ø´Â ÀÏÀÔ´Ï´Ù. ±×·¡¼­... ÃÖ¼ÒÇÑ °¡Àå Áß¿äÇÑ ºÎºÐ, ±×·¯´Ï±î ÇÐȸ °¡À̵å¶óÀο¡¼­ ±Ç°í¼öÁØÀÌ 1À¸·Î ³ª¿Â ºÎºÐ°ú ±Ù°Å¼öÁØÀÌ AÀÎ ºÎºÐÀº ȯÀÚ¿¡°Ô Àß ¼³¸íÇÑ ÈÄ ±Þ¿©À¸·Î ó¹æÇϰí ÀÖ½À´Ï´Ù. ÀÏÁ¤ ºÎºÐ »è°¨Àº ¾î¿ ¼ö ¾ø´Â ÀÏÀÔ´Ï´Ù. ¾ÆÁ÷ atrophic/metaplastic gastritis ȯÀÚ¿¡ ´ëÇÏ¿© Á¦°¡ ¸ÕÀú Á¦±ÕÄ¡·á¸¦ ±ÇÀ¯ÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. ±Ç°í¼öÁØÀÌ 2ÀÌ°í ±Ù°Å¼öÁØÀº C À̱⠶§¹®ÀÔ´Ï´Ù. (ÀϺ»°ú ´Þ¸®) ¿ì¸®³ª¶ó Àü¹®°¡µéÀº ¾ÆÁ÷±îÁö atrophic/metaplastic gastritis ȯÀÚÀÇ Á¦±ÕÄ¡·á¸¦ °­ÇÏ°Ô ±ÇÇÏÁö ¾Ê°í ÀÖ´Ù´Â ÀǹÌÀ̴ϱî¿ä. ȯÀÚ°¡ °­·ÂÈ÷ ¿ä±¸Çϸé, Çö »óȲ(ºÒ¹ýÀÓ. È¿°ú´Â Å©Áö ¾ÊÀ½. ÀÇ·áÁø°£ °ßÇØÂ÷°¡ ÀÖÀ½. ¿ì¸®³ª¶ó¸¦ »©°í ÀϺ»À̳ª ´ëºÎºÐÀÇ ±¹°¡¿¡¼­´Â Á¦±ÕÄ¡·á¸¦ Çϰí ÀÖÀ½)À» ¼³¸íÇÑ ÈÄ °­·ÂÈ÷ ¿øÇÏ¸é ²ø·Á°¡µíÀÌ ¸¶Àú ¸øÇØ Ã³¹æÇϰí ÀÖ½À´Ï´Ù. ¾ðÁ¦±îÁö ÀÌ·¸°Ô ÇÒ ¼ö ÀÖÀ»Áö ¸ð¸£°Ú½À´Ï´Ù. »è°¨ÀÌ ³Ê¹« ¸¹À¸¸é ¿¹Àüó·³ '100% ¹ýÀ» ÁöŲ´Ù'·Î µ¹¾Æ°¥ ¼ö ¹Û¿¡ ¾øÀ»Áö ¸ð¸¨´Ï´Ù. ±×·±µ¥ ¾ÆÁ÷ »è°¨ÀÌ ¸¹Àº °Í °°Áö´Â ¾Ê³×¿ä. ºñ±Þ¿© ó¹æÀº Çѹøµµ ÇØº» ÀûÀÌ ¾ø½À´Ï´Ù.

°ø·ÐÈ­ ³ë·ÂÀº ¸¹ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ½Å¹® ¹æ¼Û¿¡¼­µµ °è¼Ó ³ª¿À°í ÀÖ½À´Ï´Ù. ÇÐȸ¿¡¼­µµ ¿­½ÉÈ÷ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿¡¼­µµ Àß ¾Ë°í ÀÖ½À´Ï´Ù. ±×·±µ¥µµ ¾È ¹Ù²ãÁֳ׿ä... ÀÌ»óÇÑ ÀÏÀÔ´Ï´Ù. ´ëÇѹα¹ ±¹¹ÎÀ» À§ÇÑ ÀÏÀ» ´ëÇѹα¹ Á¤ºÎ¿¡¼­ ³ª¸ô¶ó¶ó Çϰí ÀÖÀ¸´Ï Àúµµ µµ¸®°¡ ¾ø½À´Ï´Ù. Àúµµ Á¶±Ý¾¿ ÁöÃİ©´Ï´Ù. »ý°¢µµ ÀÚ²Ù ¹Ù²ò´Ï´Ù.

[2020-2-1. ÀÌÁØÇà] Ç︮ÄÚ¹ÚÅÍ¿¡ ´ëÇÑ Á¤ºÎ ±âÁذú ÇÐȸ °¡À̵å¶óÀÎÀÌ ¹Ù²î¾î ÀÌÁ¦´Â È­»ý¼º À§¿°¿¡¼­µµ ºñ±³Àû ÀÚÀ¯·Ó°Ô Á¦±ÕÄ¡·á¸¦ Çϰí ÀÖ½À´Ï´Ù. ¾ÆÁ÷Àº Ä¡·áºñ º»ÀÎ ºÎ´ãÀÔ´Ï´Ù. ¾ÆÁÖ ´ä´äÇÑ Á¦µµÀÔ´Ï´Ù.

2017³â ¸»±îÁö´Â ±Ë¾çÀ̳ª À§¾Ï ȯÀÚ¿¡¼­¸¸ Ç︮ÄÚ¹ÚÅÍ Ä¡·á°¡ °¡´ÉÇß½À´Ï´Ù. ±×·±µ¥ 2018³â 1¿ù 1¿ùºÎÅÍ ¼ÒÈ­¼º ±Ë¾çÀ̳ª ¾Ï ȯÀÚ°¡ ¾Æ´Ï´õ¶óµµ Á¦±ÕÄ¡·á°¡ °¡´ÉÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¸¹ÀÌ ºñ½ÎÁö´Â ¾ÊÁö¸¸ "¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ"À¸·Î °áÁ¤µÇ¾ú½À´Ï´Ù.

¿øÇϽøé Á¦±ÕÄ¡·á¸¦ ó¹æÇØ µå¸± ¼ö ÀÖ½À´Ï´Ù. ¼ÒÈ­¼º ±Ë¾çÀ» ¿¹¹æÇϰí, À§¾Ï ¹ß»ý·üÀÌ ³·¾ÆÁø´Ù´Â ÁÖÀåÀÌ Àֱ⠶§¹®ÀÔ´Ï´Ù. µÎ Á¾·ùÀÇ Ç×»ýÁ¦¿Í ÇÑ Á¾·ùÀÇ À§»êºÐºñ¾ïÁ¦Á¦¸¦ 2ÁÖ Åõ¾àÇÕ´Ï´Ù.

µÎ °¡Áö À̽´°¡ ÀÖ½À´Ï´Ù. (1) ÁÖ·Î Ç×»ýÁ¦ ¶§¹®¿¡ ¼³»ç µî À§ÀåÀå¾Ö³ª ¾Ë·¯Áö¿Í °°Àº ºÎÀÛ¿ëÀÌ °¡´ÉÇÕ´Ï´Ù¸¸ °³ÀÎÂ÷´Â Å®´Ï´Ù. (2) Á¦±Õ ¼º°ø·üÀº 78.1%ÀÔ´Ï´Ù. Ä¡·á°¡ Àß µÇ¾ú´ÂÁö È®ÀÎÇϱâ À§ÇÏ¿© ¾à 8 ÁÖ ÈÄ È£±â°Ë»ç¸¦ ÇÕ´Ï´Ù.

°èȹ: 2ÁÖ 1Â÷ Á¦±ÕÄ¡·á (100/100) + 8ÁÖ ÈÄ È£±â°Ë»ç


[2023-10-28] Ç︮ÄÚ¹ÚÅÍ ½ÉÆ÷Áö¾ö


[References]

1) EndoTODAY 'À§³»½Ã°æ »ðÀÔ°ú °üÂû' 150ÂÊÀ» Âü°íÇϽʽÿÀ.

2) Atrophy & metaplastia º´º¯ÀÇ ÃßÀû°ü¸® (2009. ³»½Ã°æ¼¼¹Ì³ª °­ÀÇÀÚ·á)

3) Sun-Young Lee. Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection Korean J Intern Med 2016

4) °ËÁø¹ß°ß ¼ÒÈ­¼º ±Ë¾ç°ú ±âŸ À§½ÊÀÌÁöÀå Áúȯ À̼±¿µ. 2016³â ³»½Ã°æ ¼¼¹Ì³ª °­ÀÇ

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.